Lake Street Capital Begins Coverage on TriSalus Life Sciences (NASDAQ:TLSI)

Stock analysts at Lake Street Capital initiated coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a report released on Thursday,Briefing.com Automated Import reports. The brokerage set a “buy” rating on the stock.

A number of other research firms have also recently weighed in on TLSI. Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Northland Securities assumed coverage on TriSalus Life Sciences in a research note on Friday, October 25th. They set an “outperform” rating and a $12.50 price target on the stock. Roth Mkm reaffirmed a “buy” rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Finally, Canaccord Genuity Group cut their target price on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $11.79.

TriSalus Life Sciences Trading Up 0.4 %

TLSI stock opened at $5.61 on Thursday. The firm has a 50-day moving average price of $4.79 and a 200-day moving average price of $4.74. TriSalus Life Sciences has a 12 month low of $3.50 and a 12 month high of $10.42. The stock has a market capitalization of $171.05 million, a P/E ratio of -2.25 and a beta of 0.51.

Insiders Place Their Bets

In other news, insider Sean Murphy bought 15,000 shares of TriSalus Life Sciences stock in a transaction dated Monday, January 27th. The stock was bought at an average cost of $5.31 per share, for a total transaction of $79,650.00. Following the purchase, the insider now directly owns 182,732 shares in the company, valued at approximately $970,306.92. This represents a 8.94 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James Emmett Young purchased 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The shares were purchased at an average cost of $5.65 per share, for a total transaction of $33,900.00. Following the completion of the purchase, the chief financial officer now owns 30,000 shares in the company, valued at $169,500. This trade represents a 25.00 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 124,868 shares of company stock worth $575,843. 32.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Walleye Capital LLC acquired a new position in shares of TriSalus Life Sciences during the third quarter valued at about $66,000. Virtu Financial LLC bought a new stake in TriSalus Life Sciences during the 3rd quarter worth approximately $92,000. Vestcor Inc bought a new stake in TriSalus Life Sciences during the 3rd quarter worth approximately $108,000. MSD Partners L.P. purchased a new stake in shares of TriSalus Life Sciences in the third quarter worth approximately $184,000. Finally, Geode Capital Management LLC lifted its holdings in shares of TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after purchasing an additional 62,542 shares in the last quarter. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.